As we close out 2024, we reflect on Camber’s extraordinary year of growth and achievement. This year, we reached new heights by launching 36 new generic products, filing 35 new ANDAs, and receiving 53 ANDA approvals. These milestones have allowed Camber to provide affordable medications to a growing patient population.
Camber also made strategic investments in its workforce, welcoming new talent across our customer service, warehouse operations, supply chain, and OTC business teams, reinforcing our ability to deliver unmatched service and support.
As we look ahead to 2025, we are energized by the opportunities. Camber is set to launch an ambitious lineup of specialty medications and generic oncology products, with plans to introduce 45–50 new generic products throughout the year.
We are also investing in the future of our operations, including constructing an onsite refrigerated warehouse to accommodate our growing injectable portfolio. Additionally, we are expanding our operations and service teams and continually improving how we serve our customers and the patients who depend on them.
This success wouldn’t be possible without the hard work of our associates, the trust of our customers, and the support of our partners. Thank you for being a part of our journey. Here’s to a successful, innovative, and impactful 2025!
